文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

低甲基化药物用于VEXAS综合征的系统综述

Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review.
PubMed 文献 · Br J Haematol · 2026-01-14

该系统综述依据2020 PRISMA指南检索三个数据库,纳入30篇文献共166例基因确诊VEXAS综合征患者,评估低甲基化药物(HMA)的治疗经验。结果显示总体炎症反应率59%、血液学反应率74%,51%可检测病例实现UBA1克隆清除,毒性为最常见停药原因。

要点

  • HMA治疗VEXAS总体炎症反应率59%,完全反应52%
  • 血液学反应率74%,51%可检测病例UBA1克隆清除
  • 毒性是HMA停药最常见原因,需前瞻性研究优化方案

核心结论

  • HMA是VEXAS综合征可行的治疗选择,可诱导炎症症状改善、血细胞减少逆转及部分分子缓解。

研究设计与样本

  • 系统综述,遵循2020 PRISMA指南检索三个数据库,纳入30篇文献共166例基因确诊VEXAS综合征并接受HMA治疗的患者。

主要发现

  • 98%为男性,中位年龄71岁(范围29-86);炎症症状96%、体质症状84%、血细胞减少89%,81%合并MDS诊断。
  • p.Met41突变占81%;总体炎症反应率59%,完全反应52%,伴或不伴MDS患者均有反应。
  • 任何血液学反应率74%;在63例可检测病例中32例(51%)UBA1克隆清除至变异等位基因频率<2%。
  • 毒性是停药最常见原因。

关键数值与推荐

  • 总体炎症反应率59%,完全反应52%;血液学反应率74%。
  • UBA1克隆清除(变异等位基因频率<2%)在可检测病例中占51%(32/63)。

临床怎么用

  • 对基因确诊VEXAS综合征患者,尤其合并MDS者,可考虑HMA治疗以改善炎症和血细胞减少。
  • 治疗中需监测毒性,毒性是常见停药原因。

局限性

  • 为系统综述而非前瞻性研究,无法确定应答或耐药的预测因素及最优方案。
  • UBA1克隆清除仅在部分病例(n=63)中检测,数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is an X-linked, systemic, haemato-inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms, reverse cytopenia, enable weaning of the corticosteroids and, in some cases, induce molecular remission. We systematically reviewed the literature to evaluate the experience with HMA in the management of VEXAS, following 2020 PRISMA guidelines across three databases. A total of 30 citations reporting 166 patients with genetically confirmed VEXAS syndrome treated with HMA were included. All but three patients were males (98%), and the median age was 71 years (range, 29-86). Inflammatory symptoms (96% of patients), constitutional symptoms (84%) and cytopenia (89%) were most frequently reported, and 81% had a concomitant diagnosis of myelodysplastic syndromes (MDS). Most mutations were substitutions of p.Met41 (81%). Overall inflammatory response was achieved in 59% of treated patients with most complete response (52%). Responses were documented in patients with and without concomitant MDS. Any haematological response was achieved in 74% of the patients, and eradication of the UBA1 clone (to a variant allele fraction of <2%) was detected in 51% of cases in whom mutation testing was performed (n = 32/63). Toxicity was the most frequent reason for discontinuation of therapy. This review highlights HMAs as a feasible option in the management of VEXAS syndrome. Prospective studies are needed to identify predictors for response or resistance and optimal regimens.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hoff FW, Trikha R, Groarke EM, et al. Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review. Br J Haematol. 2026. PMID: 41531276. doi:10.1111/bjh.70302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。